Ken Hatogai
Overview
Explore the profile of Ken Hatogai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
389
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Matossian M, Shiang C, Dolcen D, Dreyer M, Hatogai K, Hall K, et al.
Breast Cancer Res Treat
. 2024 Nov;
209(3):563-572.
PMID: 39579248
Purpose: In early-stage, triple-negative breast cancer (TNBC), immune cell infiltration contributes to cancer cell survival, tumor invasion, and metastasis. High TNBC glucocorticoid receptor (GR) expression in early-stage TNBC is associated...
2.
Ziblat A, Horton B, Higgs E, Hatogai K, Martinez A, Shapiro J, et al.
Cell Rep
. 2024 Apr;
43(5):114141.
PMID: 38656869
The cellular source of positive signals that reinvigorate T cells within the tumor microenvironment (TME) for the therapeutic efficacy of programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade has not been...
3.
Higgs E, Bao R, Hatogai K, Gajewski T
J Immunother Cancer
. 2022 Jun;
10(6).
PMID: 35705315
Background: A T cell-rich tumor microenvironment has been associated with improved clinical outcome and response to immune checkpoint blockade therapies in several adult cancers. Understanding the mechanisms for lack of...
4.
Verset G, Borbath I, Karwal M, Verslype C, Van Vlierberghe H, Kardosh A, et al.
Clin Cancer Res
. 2022 Apr;
28(12):2547-2554.
PMID: 35421228
Purpose: KEYNOTE-224 cohort 1 demonstrated that pembrolizumab was efficacious and tolerable in patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib. We report results from KEYNOTE-224 (NCT02702414) cohort 2,...
5.
Rouhani S, Trujillo J, Pyzer A, Yu J, Fessler J, Cabanov A, et al.
Res Sq
. 2021 Nov;
PMID: 34845442
The mechanisms explaining progression to severe COVID-19 remain poorly understood. It has been proposed that immune system dysregulation/over-stimulation may be implicated, but it is not clear how such processes would...
6.
Reschke R, Yu J, Flood B, Higgs E, Hatogai K, Gajewski T
J Immunother Cancer
. 2021 Oct;
9(9).
PMID: 34593622
A T cell-inflamed tumor microenvironment is characterized by the accumulation and local activation of CD8 T cells and Bat3-lineage dendritic cells, which together are associated with clinical response to anti-programmed...
7.
Hatogai K, Sweis R
Adv Exp Med Biol
. 2021 Jun;
1296:275-290.
PMID: 34185299
Bladder cancer has been well known as immunotherapy-responsive disease as intravesical therapy with BCG has been the standard of care for non-muscle invasive disease for several decades. In addition, immune...
8.
Hatogai K, Kato Y, Hirase C
Acta Oncol
. 2021 Jan;
60(2):143-148.
PMID: 33460336
Background: Comparative studies often cannot be conducted for cancer types with a small patient population. We reviewed the efficacy evaluations of new drug approvals in Japan based on the results...
9.
Yamamoto Y, Kadota T, Yoda Y, Hori K, Hatogai K, Kojima T, et al.
Esophagus
. 2020 Apr;
17(4):433-439.
PMID: 32232702
Backgrounds: Local recurrence after definitive chemoradiotherapy, if diagnosed early, can be cured by salvage endoscopic therapy, which allows organ preservation and contributes to maintaining patient quality of life. This study...
10.
Hatogai K, Fujii S, Kitano S, Kojima T, Daiko H, Yoshino T, et al.
Br J Cancer
. 2019 Nov;
122(3):413-420.
PMID: 31761900
Background: Tumour microenvironments can differ according to intratumoural locations. We investigated the immune status at different locations in primary tumours and its clinical significance in oesophageal squamous cell carcinoma (ESCC)....